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Abstract 
 
Purpose: To evaluate the role of cytochrome 450 2D6 (CYP2D6) and ABCB1 variants on plasma risperidone 
concentrations and treatment response in 83 drug naive patients with first episode of psychosis.  
Methods: All patients were treated with risperidone for 8 weeks. The CYP2D6 genotyping was performed by 
allele-specific PCR-RFLP (for *3,*4,*6) and long PCR (for duplications and *5), while real-time PCR method 
was used for ABCB1 G2677T/A and C3435T. Plasma concentrations of risperidone and 9-OH risperidone were 
measured by high-preformance liquid chromatography.  
Results: The number of patients with the CYP2D6 wild type (wt/wt), wt/mutation (mut) and mut/mut genotype 
was 43, 32 and 8, respectively. The number of patients with the ABCB1 2677G/G , G/T, T/T variants was 29, 42 
and 12, respectively; those with the 3435C/C, C/T  and  T/T was 25, 37 and 21, respectively. The CYP2D6 
genotype has strong effect on steady-state dose-corrected plasma levels of risperidone, its 9-OH metabolite and 
active moiety, while ABCB1 2677T/T and 3435T/T genotypes hold similarly strong effects on active moiety 
C/D. The CYP2D6 poor metabolizers had significantly higher levels of risperidone C/D and active moiety C/D, 
and lower levels of 9-OH risperidone C/D. The ABCB1 3435T allele and the ABCB1 2667T-3435T haplotype 
carriers were more frequent among subjects without extrapyramidal syndrome. Patients showed significant 
improvements in positive and general symptoms, but not in negative symptoms. These changes were not related 
to variations in genetic and drug concentration data.  
Conclusion: Our findings suggest that CYP2D6 and ABCB1 G2677T and C3435T might be useful determinants 
of risperidone plasma concentrations, but the clinical implications of these associations in relation to treatment 
response and side-effects remains unclear.  
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Introduction 
 
Everyday clinical experience suggests that patients with schizophrenia significantly vary in their response to 
antipsychotic treatment. The patients with first episode of psychosis fall into the same category. However, 
without confounding effects of illness chronicity and previous antipsychotic treatments, their variability in 
treatment response could be significantly related to drug metabolic polymorphisms [1].  
 
Risperidone is a widely used antipsychotic drug with potent antagonistic properties for dopamine D2 and 
serotonin 5-HT2 receptors. Its active metabolite 9-hydroxyrisperidone (9-OH-risperidone) is approximately 
equipotent with the parent drug in dopamine receptor affinity. Therefore, the entire active moiety (risperidone + 
9-OH-risperidone) is regarded to contribute to the full antipsychotic effect [2]. According to in vivo and in vitro 
studies, cytochrome CYP2D6 is responsible for the metabolism of risperidone [3, 4]. Several mutated alleles of 
CYP2D6 gene might cause its absent (e.g. CYP2D6*3, CYP2D6*4, CYP2D6*5), or even increased activity 
(CYP2D6*2xN) [5]. Risperidone has strong affinity for P-glycoprotein (P-gp), a transporter that regulates drug 
bioavailability by controlling intestinal drug absorption, renal excretion and transport across the blood-brain 
barrier [6]. P-gp is a member of the adenosine triphosphate-binding cassette (ABC) superfamily and the ABCB1 
gene encodes its expression [7]. Both single-nucleotide polymorphisms, exon 21 (G2677T/A), missense 
polymorphism within exon 21(rs2032582) and silent mutation C3435T in exon 26 (rs1045642) are associated 
with a lower level of intestinal ABCB1 expression [8].   
 
Since certain cytochrome enzyme CYP2D6 and ABCB1 variants have different functional capacity, genotyping 
may be a clinically useful tool for antipsychotic therapy individualization, mainly dose optimization and 
prevention of the drug's adverse effects. It has been shown that CYP2D6 genotypes have significant effect on 
steady-state plasma levels of risperidone and 9-OH risperidone [9], but ABCB1 variants’ effect vary from 
moderate [10] to completely absent [11]. However, this is the first study to search for these effects in drug naïve 
patients with first episode of psychosis. Our aim was to evaluate the role of CYP2D6 and ABCB1 variants in 
therapeutic efficacy and safety after eight weeks of treatment with orally administered risperidone. 
 
Methods 
 
Subjects  
 
The study included 83 subsequently hospitalized patients who met the following criteria: (a) an ICD-10 
diagnosis of first episode of schizophrenia spectrum disorder [12]; (b) drug naïve status in terms of using 
antipsychotics; (c) initiation of risperidone treatment based on the standard clinical practice. All were treated 
with orally administered risperidone and followed-up for eight weeks. No other psychotropic medication was 
prescribed, except anticholinergics (biperiden) for the alleviation of extrapyramidal symptoms (in 44 patients, 
mean dose 2.74 mg ± 1.6) and benzodiazepines (diazepam) as hypnotics (in 37 patients, mean dose 7.21mg ± 
3.09). The sample was predominantly female (N=66, 79.5%) and average age was 30.3± 8.1. Majority were 
smokers (N=45, 54.2%), single (N=45, 54.2%) and with high school education (N=63, 75.9%). Approximately 
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one third had a case of psychosis in their family (N=25, 30.1%). Mean body weight was 74.26 kg ± 11.49. The 
clinical and demographic data for these patients are given in Table 1. 
 
All participants were of Croatian origin. Out of 101 patients initially invited to participate in the study, six 
refused to be included and three were excluded from the final analyses due to incomplete follow-up data. In 
seven cases patients' condition got significantly worse several days before the study end-point and clinicians 
were forced to increase the drug's dose (n=4) or switch to another antipsychotic (olanzapine, n=2 and 
fluphenazine, n=1), thus disabling the measurement of the drug's concentration at the end-point. In order to stick 
to the original study design as much as possible, it was our decision to exclude these patients from the further 
analysis. Two additional subjects were excluded because their risperidone and 9-OH risperidone’s concentrations 
were lower than limit of detection.  Even though all participants were inpatients and drugs were given under the 
supervision of hospital nurses, it might be possible that they were not using the drug at all. The study was 
performed at the University Hospital Centre Zagreb, Department of Psychiatry, from 2006. - 2009. as part of the 
project “Effects of pharmacogentic variants on pathogenesis of schizophrenia and treatment response”. The 
study protocol was approved by the institutional ethical committee and all participants gave written informed 
consents.  
 
------------------------------ 
Insert Table 1 about here 
------------------------------ 
 
Clinical assessment 
 
Baseline clinical assessment consisted of structured psychiatric interview, collection of sociodemographic data, 
severity of psychopathology (using the Positive and Negative Syndrome Scale, PANSS) [13], tobacco use, 
physical examination and body weight measurements.  PANSS was rated by two trained raters (V.M. and N.J.) 
and inter-rater reliability was 0.76. Both raters were blind to the genotype- and plasma concentration data. The 
Simpson-Angus scale was used for the evaluation of extrapyramidal symptoms and patients with score ≥ 3 were 
classified as the EPS+ group [14]. Patients were also assessed for other side-effects such as amenorrhea, 
galactorrhea  and gynecomastia. 
 
Genotyping 
 
Patients were genotyped for CYP2D6 by means of allele-specific polymerase chain reaction and restriction 
fragment length polymorphism (PCR-RFLP) for CYP2D6*3,*4,*6 alleles, and by long PCR for CYP2D6* 
duplication and CYP2D6 *5 alleles in Thermocycler 9700, Applied Biosystems [15]. For ABCB1 2677G>T/A, 
and 3435C>T Real-time PCR method was applied in LightCycler (Roche), with Fast Start DNA Master plus 
HybProbe master mix [16-18]. 
  
Plasma concentrations 
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Samples were collected after eight weeks of treatment and after a minimum of 15 days of stable dose of the drug. 
The dosage of risperidone was completely left up to a clinician’s decision, based on the rules of good clinical 
practice. Blood samples were obtained in the morning (07.00 h), 12 hours after the bedtime dose and before the 
morning dose. Plasma concentrations of risperidone and 9-hydroxyrisperidone (TRC, Canada) were measured by 
high performance liquid chromatography (HPLC) method with diode array detector (Shimadzu, Japan) [19]. 
Compounds are separated using linear gradient on Symmetry C18 (Waters) column. Solvent A was acetonitril 
and solvent B consisted of 0.05 M NaH2PO4xH2O pH 3.8. The gradient ratio of solvent B started at 25%, rising 
up to 60% during the 25 minute period. Flow rate was 1,5 ml/min and oven was set at 45°C. The eluted 
substance was detected at 200 nm (fluoxetine as internal standard) and 277 nm (risperidone and 9-OH 
risperidone). All compounds were confirmed with standard UV spectra 190-370 nm. One milliliter of plasma 
was mixed with 50 µL of the aqueous internal standard solution and 100 µL of 0.5 M NaOH. The mixture was 
vortexed for 3 seconds, and 5 ml of extraction solvent was added (hexan-ethyl acetate 1:1) then shaken and 
centrifugated. Four milliliters of organic layer evaporated to dryness at 37°C. The residue was dissolved in 150 
µl of mobile phase. The method was validated for concentration range 12 – 244 nmol/L for risperidone and  12-
234 nmol/L for 9-OH risperidone. Limit of detection was 6.1 and 5.8 nmol/L for analytes respectively. Accuracy 
at three concentrations  ranged from 94.3 to 103.6 %.  Inter and intra-day relative standard deviations were lower 
than 12 %. This analytes are included in external quality control scheme (UK NEQAS).  
 
Statistical Analysis 
 
All statistical analyses central to the aim of this study were performed with the following genotype groups: 
CYP2D6 wt/wt, wt/mut and mut/mut, ABCB1 2677G/G, G/T, T/T and ABCB1 3435C/C, C/T, T/T. Furthermore, 
ABCB12677 alleles G and T, and ABCB1 3435 alleles C and T were analysed separately in a logistic regression 
model described in details below. Haplotype analysis was performed on the C3435T and G2677T variants on the 
basis of linkage disequilibrium observed between both positions. Steady-state plasma concentrations of 
risperidone and 9-hydroxyrisperidone were adjusted by drug dosage (dose-corrected values) and presented as 
geometric means and 95% confidence interval. Active moiety concentration stands for the sum of risperidone 
and 9-OH risperidone concentrations. Differences in plasma drug concentrations (C/Ds) between different 
genotypes were analysed using Kruskal-Wallis test with Mann Whitney test for post hoc comparisons. Due to 
multiple comparisons, level of statistical significance for the Mann Whitney test is decreased to p<0.017. 
Interval measures were presented as means with standard deviations. Chi-square tests were used to compare the 
groups for different categorical variables. Differences in psychopathology (measured by PANSS) were examined 
using one-way ANOVA (all results statistically non significant) and paired sample t-test. A binary logistic 
regression model was created to identify which genetic variant predicted best the patients' clinical response to 
treatment. The latter was dichotomized depending on weather the individual value was below or above 50% 
improvement in total PANSS score and used as a dependent variable in the model. Independent variables were: 
age, gender, CYP2D6, ABCB1 G2677T and ABCB1 C3435T genotypes (each as wt/wt, wt/mut and mut/mut), 
ABCB12677 alleles (G and T), ABCB1 3435 alleles (C and T). The Statistical Package for the Social Sciences 
(SPSS, Chicago, IL) version 12 was used for all the abovementioned analyses.  
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Results 
 
The CYP2D6 and ABCB1 genotype distribution 
 
The distribution of the analyzed CYP2D6 genotypes wt/wt, wt/mut and mut/mut was 43, 32 and 8, respectively. 
Only one patient carried more than two copies of a functional CYP2D6 allele (ultrarapid metabolizer) and was 
excluded from the final analysis. Their risperidone concentration was 0 nmol/L and 9-OH risperidone was 56 
nmol/L which is in agreement with their ultraextensive metabolic phenotype. Concerning the ABCB1 2677G/G, 
2677G/T, 2677T/T genotypes, the distribution was 29, 42 and 12, respectively. None of the participants carried a 
2677A allele. Furthermore, a total of 25 patients were the ABCB1 3435C/C carriers, while 37 carried the 
3435C/T and 21 the 3435T/T. Data presented in Table 2. The two single nucleotide polymorphisms were in 
linkage disequlibrium (D’=0.78) and the most frequent ABCB1 haplotype was 2677G - 3435C (0.318), followed 
by the 2677T - 3435T (0.265), the 2677G - 3435T (0.238) and the 2677T - 3435C (0.179). There were no 
differences between these genotype subgroups in regard to any of the studied sociodemographic or clinical 
variables, including PANSS scores at baseline and end-point.  
 
------------------------------ 
Insert Table 2 about here 
------------------------------ 
 
The steady-state plasma concentrations 
 
The drug was prescribed at the mean dose of 3.96 mg ± 1.5 (range 1-8 mg). The schemes were as follows: “8 
mg/day” (n=3), “7 mg/day” (n=1), “6 mg/day” (n=7), “5 mg/day” (n=4), “4 mg/day” (n=30), “3 mg/day” (n=22), 
“2 mg/day” (n=15) and “1 mg/day” (n=1). Dose-corrected plasma levels (C/Ds) of risperidone, 9-OH risperidone 
and active moiety C/D (risperidone + 9-OH risperidone) are given in Table 2.  In general, the CYP2D6 genotype 
holds a statistically significant effect on risperidone C/D (Kruskal-Wallis Test: 16.161, df=2 p<0.001), 9-OH 
risperidone C/D (9.699, df=2, p=0.008) and active moiety C/D (9.142, df=2, p=0.01). The ABCB1 G2677TA 
genotypes have significant effect only on the active moiety C/D (Kruskal-Wallis Test: 13.478, df=2, p=0.001). 
The ABCB1 C3435T genotypes have statistically significant effect on risperidone C/D (6.351, df=2, p=0.042) 
and active moiety C/D (14.744, df=2, p=0.001).  
 
The role of the CYP2D6 poor metabolizers (PMs) 
 
A total of 8 patients were genotyped as the CYP2D6 poor metabolizers (genotype CYP2D6 mut/mut). They had 
significantly higher levels of risperidone C/D than homozygous EMs (genotype CYP2D6 wt/wt; Mann Whitney 
U=1.00, Z = -3.83, p<0.001) and heterozygous EMs (genotype CYP2D6 wt/mut; U=8.00, Z = -3.38, p<0.001). 
The same pattern was observed in regard to active moiety C/D – PMs had significantly higher levels of active 
moiety C/D than homozygous EMs (U=30.00, Z = -2.73, p=0.004) and heterozygous EMs (U=34.00, Z = -2.12, 
p=0.033). However, PMs have significantly lower levels of 9-OH risperidone C/D than homozygous EMs 
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(U=49.000, Z = -2.03, p=0.045) or heterozygous EMs (U=21.000, Z = -2.8, p=0.004). The Risperidone/9-OH 
risperidone ratio was >1 in PMs, thus indicating lack of CYP2D6 activity. Furthermore, the same ratio was 
higher in PMs than in homozygous EMs (U=0.00, Z= - 3.864, p<0.001) or heterozygous EMs (U=6.00, Z= - 
3.457, p<0.001). Please see Figure 1 and Table 2. 
 
The role of ABCB1 genotypes on differences in drug concentrations 
 
The ABCB1 2677T/T genotype is associated with higher levels of dose-corrected active moiety than ABCB1 
2677G/G genotype (Mann Whitney U=25.00, Z = -3.151, p=0.001) and than ABCB1 2677G/T genotype (Mann 
Whitney U=30.00, Z = -3.356, p<0.001). The ABCB1 3435T/T genotype is associated with higher levels of 
risperdone C/D than the 3435C/C genotype (Mann Whitney U=73.00, Z = -2.529, p=0.011). Similarly, the 
carriers of the 3435T/T genotype have higher levels of active moiety C/D than those who carry the 3435C/C 
(Mann Whitney U=43.00, Z = -3.508, p<0.001) or the 3435C/T genotype (Mann Whitney U=88.00, Z = -2.830, 
p=0.004). 
 
The clinical response 
 
No statistically significant difference was found when comparing genotype groups for baseline and end-point 
(after 8 weeks of treatment) PANSS scores (Table 3). Likewise, no statistically significant correlations were 
found between the PANSS scores and plasma concentrations (p>0.05). However, majority of our patients did 
show decrease in symptom severity. In comparison to baseline, greatest benefits were seen in reduced scores on 
the positive symptoms subscale (t-test: t=14.356, df=82, p<0.001), general psychopathology subscale (t=10.558, 
p<0.001) and total PANSS score (t=10.181, p<0.001), but the difference was not significant for the negative 
symptoms score (t=1.6, p=0.114). Our next step was to search for the predictive value of these genotypes 
(CYP2D6 wt/wt, wt/mut, mut/mut, ABCB1 C3435T and G2677T/A) and ABCB1 alleles (ABCB1 3435 G and T, 
ABCB1 2677 C and T) on the clinical response (defined as 50% improvement from baseline in total PANSS). 
Following this criteria, a total of 21 participants (25.3%) were responders. After adjusting for confounding 
factors, our regression model showed no statistically significant predictors (p>0.05; data not shown). 
The only significant difference was that fewer people with EPS were among the responders (6/21, chi square 
5.697, df=1, p=0.017). No other differences in genotype, plasma concentrations or general data were present.  
 
  
------------------------------ 
Insert Table 3 about here 
------------------------------ 
 
The extra-pyramidal and other side-effects 
 
We found that 44 patients (53.01%) had EPS (Simpson-Angus scale > 3). Interestingly, when analyzing the EPS- 
group (N=39, 46.9%), there were significantly more ABCB1 2667T-3435T haplotype carriers (N=17, chi square 
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4.140, df=1, p=0.042) and ABCB1 3435T allele carriers (N=29, chi square 5.8, P=0.016). No other difference in 
respect to demographic, clinical or genetic data was found. No statistically significant correlations were found 
between the score on Simpson-Angus scale and plasma concentrations (p>0.314). Considering other serious 
side-effects, eleven women reported amenorrhea (13.3 %), three suffered from galactorrhea (3.6 %) and one had 
gynecomastia (1.2 %). Two patients had EPS, amenorrhea and galactorrhea at the same time. 
 
Discussion 
 
Our results suggest that CYP2D6 genotype has significant influence on the steady-state dose-corrected levels of 
risperidone, 9-OH risperidone and active moiety which is in accordance with some previously conducted studies 
on Italian [10], Japanese [11] and Korean [20] subjects with schizophrenia. This is the first time to replicate 
these results on a Croatian (Slavic) population.  
 
Out of all CYP2D6 phenotypes, poor metabolizers are of highest significance for clinicians because this group is 
at risk for adverse reactions to medications and may reach toxic levels of medications at relatively low clinical 
doses. As expected, the poor metabolizers in the present study were characterized with significantly higher levels 
of steady state dose-corrected risperidone and lower levels of dose-corrected 9-OH risperidone. Furthermore, the 
CYP2D6 poor metabolizer phenotype was associated with the risperidone/9-OH risperidone ratio >1 which 
indicates the lack of CYP2D6 activity. What we also found was that the frequency of PMs in our sample was 
9.6% which is three times higher than for the general population in Croatia (3%), while the frequencies of other 
two CYP2D6 genotypes did not differ much from the general population data [21]. This was a surprising and 
difficult to explain finding especially since these are patients with the first episode of psychosis and not 
treatment resistant or high level of adverse effects group. We did not show that they have significantly more 
side-effects or different treatment response than others, but our results should be interpreted with caution due to 
small number of subjects. A study on much larger sample of 325 persons stabilized on risperidone therapy found 
that the CYP2D6 poor metabolizer phenotype triples the risk for moderate-to-marked adverse drug reactions and 
drug discontinuation. [22].  
 
Concerning the ABCB1 genotypes, the strongest effect was seen between ABCB1 2677T/T and ABCB1 
3435T/T genotypes and increased level of risperidone active moiety C/D. The presence of 3435T/T genotype 
might reduce expression and activity of P-gp, thus limiting intestinal drug absorption and central nervous system 
penetration [8, 23]. We have also found that half of our subjects had extrapyramidal symptoms. However, the 
other half (EPS- group) was characterized with significantly more ABCB1 3435T allele and ABCB1 2667T-
3435T haplotype carriers. There was no difference in plasma levels in regard to these features. This finding 
suggests that ABCB1 3435T allele and/or ABCB1 2667T-3435T haplotype variants may not be such strong 
mediators of drug’s penetration into central nervous systems after all. Even though two other studies reported 
that higher plasma concentrations of active moiety tends to be associated with a higher rate of extrapyramidal 
symptoms [24, 25], it might be hard to establish a straightforward and firm association between drug’s levels 
peripherally and centrally. Since 9-OH risperidone has been marketed as a separate antipsychotic (paliperidone), 
we would like to discuss our findings about 9-OH risperidone in more details. In an attempt to combine our 
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results and effects of CYP2D6 and ABCB12677T/T and 3435T/T genotypes, we can say that the level of dose-
corrected 9-OH risperidone is significantly lower in CYP2D6 PMs, while ABCB1 genotype holds no effect on 
this metabolite. Therefore, there are no additive effects between these genetic variants and it might be suggested 
that determination of these ABCB1 genotypes has very little clinical importance considering individualization of 
paliperidone treatment. However, these findings need to be replicated since two other studies on Caucasian men 
reported that the ABCB1 2677T/T carriers had significantly lower 9-OH risperidone levels [10, 26].  
 
We found no clear association between the genotype and plasma concentration differences and treatment 
response to eight weeks of risperidone, thus leaving this extremely important question still opened. Results from 
a recent study on 59 Slovenian patients with the first episode of schizophrenia, also treated with risperidone, 
indicate that heterozygous carriers of G2677T/A and C3435T polymorphism scored somewhat higher on scales 
measuring psychopathology and extrapyramidal side effects, but the difference was not significant and there was 
no tendency of gene-dose effect [27]. Interestingly, in our previous study we did find positive associations 
between ABCB1 2677T allele and 2677T/T genotype and better treatment response in female patients with 
schizophrenia who were treated with another atypical antipsychotic – olanzapine [28]. What we found here was 
that after 8 weeks of risperidone treatment a quarter of our patients had 50% lower level of symptom severity 
(responders). There were significantly fewer people with EPS were among them. Significant improvements were 
observed in positive and general symptoms, but not in negative symptoms. This finding is probably contributable 
to the fact that risperidone may not be very efficient in reducing negative symptoms, rather than to not so high 
level of negative symptoms early in the course of schizophrenia in our patients. Secondly, this finding holds an 
important message to clinicians working with this group of patients especially because it has been shown that 
early non-response (as early as 1 or 2 weeks) can reliably predict subsequent non-response to treatment of 
schizophrenia [29, 30]. 
 
Main study limitation is relatively small sample size. It might be necessary to analyse much larger samples to 
show clear effects of drug metabolic polymorphisms on clinical outcome. However, strengths are related to the 
sample type (drug naive patients) and naturalistic design (hopefully this might help clinicians in translating these 
results into reality of their clinical practice). 
 
In conclusion, the present study suggests that CYP2D6 genotype has strong effect on steady-state dose-corrected 
plasma levels of risperidone, its 9-OH metabolite and active moiety, while ABCB1 2677T/T and 3435T/T 
genotypes hold similarly strong effects on active moiety. Additionally, the ABCB1 3435T/T genotype has 
somewhat weaker influence on risperidone C/D. Clinically significant group of CYP2D6 poor metabolizers were 
characterized with significantly higher levels of dose-corrected risperidone and active moiety, and lower levels 
of dose-corrected 9-OH risperidone. Those with extrapyramidal syndrome did not differ in drug plasma 
concentrations. However, the ABCB1 3435T allele and the ABCB1 2667T-3435T haplotype carriers were more 
frequently present among subjects without extrapyramidal syndrome. Even though patients did show significant 
improvements in positive and general symptoms, but not in negative symptoms, these changes were not related 
to variations in genetic and drug concentration data. Therefore, our findings suggest that CYP2D6 and ABCB1 
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G2677T and C3435T might be useful determinants of risperidone plasma concentrations, but clinical 
implications of these findings in relation to treatment response and side-effects remains unclear.  
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Table 1 – General, clinical and side-effects data for all subjects included in the study 
 
 All subjects 
N=83 
Gender, M/F, N (%) 17, 20.5 / 66, 79.5 
Age, years (mean ± SD) 30.3 ± 8.1 
Marital status, N (%)  
- Single  45 (54.2) 
- Married 31 (37.3) 
- Divorced 7 (8.4) 
Education, N (%)  
- primary school  7 (8.4) 
- high school 63 (75.9) 
- college 13 (15.7) 
Smokers, N (%)  45 (54.2) 
Body weight, kg (mean ± SD) 74.26 ± 11.5 
Family history of psychosis, N (%) 25 (30.1) 
Baseline total PANSS score (mean ± SD) 95.3 ± 17.7 
End-point total PANSS score (mean ± SD) 62.97 ± 23.4 
Percentage of change in PANSS total score (mean ± SD) 32.09 ± 29.01 
Responders to 8 weeks of risperidone treatment, N (%) 23 (27.7) 
Dosage of risperidone at the study end-point (mean ± SD) 
3.96 ± 1.5 
Concomitant therapy, mg (mean ± SD)  
- anticholinergic 2.74 ± 1.6 
- diazepam 7.21 ± 3.1 
Side-effects to treatment, N (%)  
- EPS+ subjects  44 (53.01) 
- amenorrhea 11 (13.3) 
- galactorrhea 3 (3.6) 
- gynecomastia 1 (1.2) 
 
Note. PANSS stands for Positive and Negative Syndrome Scale. Response to treatment is defined as 50% 
improvement from baseline total PANSS score. EPS+ subjects are those experiencing extrapyramidal symptoms 
(score ≥ 3 on the Simpson-Angus scale for extrapyramidal symptoms)  
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Table 3 – Influence of CYP2D6, ABCB1 G2677T/A and ABCB1 C3435T genotypes on 
symptom severity on admission (baseline) and after 8 weeks of risperidone treatment (study 
end-point). 
 
    ANOVA* 
CYP2D6 wt/wt 
N=43 
wt/mut 
N=32 
mut/mut 
N=8 
 
Baseline PANSS     
  Positive subscale 26.08±6.6 25.9±6.3 27.6±5.7 0.782 
  Negative subscale 21.21±8.34 22.4±11.13 19.4±3.96 0.699 
  General psychopathology subscale 46.84±9.67 48.97±11.9 47.8±12.2 0.731 
  Total score 94.39±15.41 97.14±14.6 94.8±16.3 0.822 
Study end-point PANSS     
  Positive subscale 12.31±6.4 13.43±5.41 15.25±5.8 0.418 
  Negative subscale 18.87±11.24 19.11±10.55 4.9±1.74 0.959 
  General psychopathology subscale 30.63±10.13 29.89±8.79 32.6±11.8 0.786 
  Total score 61.82±16.3 62.81±16.5 65.3±10.9 0.931 
ABCB1 G2677T G/G 
N=29 
G/T 
N=42 
T/T 
N=12 
 
Baseline PANSS     
  Positive subscale 27.56±5.21 25.64±6.9 24.33±6.13 0.274 
  Negative subscale 20.81±8.24 20.64±7.5 25.81±14.75 0.236 
  General psychopathology subscale 48.37±11.02 48.43±10.03 44.00±12.6 0.460 
  Total score 96.74±17.71 95.10±18.29 93.72±18.31 0.883 
Study end-point PANSS     
  Positive subscale 13.03±5.6 13.69±6.34 11.00±5.6 0.428 
  Negative subscale 18.63±12.3 16.42±7.03 21.00±13.09 0.120 
  General psychopathology subscale 31.74±9.23 29.63±10.57 30.72±8.43 0.702 
  Total score 63.4±18.93 59.75±12.81 68.72±14.98 0.515 
ABCB1 C3435T C/C 
N=25 
C/T 
N=37 
T/T 
N=21 
 
Baseline PANSS     
  Positive subscale 26.54±6.1 26.52±6.6 24.63±6.04 0.521 
  Negative subscale 20.7±8.5 20.4±7.7 24.6±8.24 0.269 
  General psychopathology subscale 46.4±11.2 49.23±9.3 46.7±12.9 0.561 
  Total score 93.6±18.3 96.44±17.5 96.23±18.9 0.828 
Study end-point PANSS     
  Positive subscale 12.7±5.5 13.4±6.6 12.94±5.5 0.900 
  Negative subscale 19.4±8.95 15.5±6.7 24.35±8.8 0.136 
  General psychopathology subscale 31.2±9.3 29.7±10.9 31.4±7.96 0.790 
  Total score 63.2±12.8 58.6±12.6 68.7±8.8 0.340 
Note. PANSS stands for Positive and Negative Syndrome Scale. 
*All results are statistically non-significant (p>0.05). 
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Figure 1A 
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Figure 1B 
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Figure 1C 
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Figure 1D 
 
 
